Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Mattes

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Archives of General Psychiatry|February 9, 2000
Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study GroupC H van Dyck, P Newhouse, W E Falk, et al.
Biological Psychiatry|February 1, 1990
A placebo-controlled evaluation of vasopressin for ECT-induced memory impairmentJ A Mattes, H M Pettinati, S Stephens, et al.
Psychopharmacology Bulletin|January 1, 1989
Vasopressin for ECT-induced memory impairment: a placebo-controlled comparisonJ A Mattes, H M Pettinati, S M Nilsen, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Archives of General Psychiatry|February 9, 2000
Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study GroupC H van Dyck, P Newhouse, W E Falk, et al.
Biological Psychiatry|February 1, 1990
A placebo-controlled evaluation of vasopressin for ECT-induced memory impairmentJ A Mattes, H M Pettinati, S Stephens, et al.
Psychopharmacology Bulletin|January 1, 1989
Vasopressin for ECT-induced memory impairment: a placebo-controlled comparisonJ A Mattes, H M Pettinati, S M Nilsen, et al.
Pageof 6